Dyspareunia Clinical Trial
Official title:
A Cognitive Behavioral Group Program-plus for Women With Dyspareunia: A Randomized Waiting List Controlled Multi-center Trial of Efficacy
The current study will employ a group CBT treatment program of 10 group sessions and 3 individual couple sessions targeting the thoughts, emotions, behaviors and couple interactions associated with the experience of dyspareunia. Women with superficial dyspareunia and their partners will be randomized to the CBT group program-plus or a waiting list control period at one treatment location in Sweden and two treatment locations in the Netherlands. The waiting-list control period will be comparable to the treatment duration of six months. It is hypothesized that the group program-plus is more effective in improving pain during intercourse in women with superficial dyspareunia compared to women on a waiting-list control period.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - woman - 18-45 years old - in a heterosexual relationship for at least 3 months - diagnosis of superficial dyspareunia (in accordance to DSM5) with no apparent ongoing physical cause to the condition (i.e. ongoing infections). - past experience of a successful intercourse - attempted intercourse during the last year Exclusion Criteria: - reporting to never have had full intercourse at any time in life - partner not willing to participate in the study - major affective disorder, psychotic disorder, substance-related disorder or post traumatic-stress disorder related to the genitals (e.g., as a sequel to sexual abuse) according to DSM-5 criteria - being pregnant - gone through child delivery during the last year - not speaking Dutch or Swedish well enough to participate in assessment and treatment - receiving concurrent psychological therapy or physiotherapy for superficial dyspareunia during CBT or WLC period. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Leiden University Medical Center, Department of Gynecology | Leiden | |
Netherlands | Maastricht Universiy Medical Center (MUMC) | Maastricht | |
Sweden | Center for Health and Medical Psychology (CHAMP) Örebro University | Örebro |
Lead Sponsor | Collaborator |
---|---|
Örebro University, Sweden | Leiden University Medical Center, Maastricht University Medical Center |
Netherlands, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient Health Questionnaire (PHQ-9) | Symptoms of depression will be assessed with the 9 item Patient Health Questionnaire (PHQ-9). The answers are given on a scale between 0-3 and total scores ranges between 0-27 with higher scores indicative of higher symptoms of depression. | 6 months; 9 months; 12 months | |
Other | Generalized Anxiety Disorder-7 (GAD-7) | Symptoms of anxiety will be assessed with the 7 item generalized anxiety disorder-7 (GAD-7). The answers are given on a scale between 0-3 and total scores ranges between 0-21 with higher scores indicative of higher symptoms of anxiety. | 6 months; 9 months; 12 months | |
Other | International Index of Erectile Dysfunction (IIEF) | Male sexual function will be assessed with the 15 items of the International Index of Erectile Function (IIEF) which is a widely used, multi-dimensional self-report instrument for the evaluation of male sexual function. The answers are given on a Likert scale ranging from 0 or 1 to 5, depending on item. For the current study, the total IIEF score will be used, which gives an indication of the sexual functioning during the past four weeks. The total score ranges between 2-30 with higher scores indicating higher sexual function. | 6 months; 9 months; 12 months | |
Other | Male Sexual Distress Scale (MSDS) | Sexual related personal distress will be assessed with the 12-item Female Sexual Distress scale (FSDS). Because the FSDS does not contain gender specific items, the measure has also successfully been administered to male participants. Questions are answered on a 0-4 Likert scale and the total score ranges from 0-48 with higher scores indicating higher sexual distress. | 6 months; 9 months; 12 months | |
Other | Perceived treatment improvement and satisfaction | Self-reported improvement (scale of 0 (worse) to 5 (complete cure)) and treatment satisfaction (scale of 0 (completely dissatisfied) to 10 (completely satisfied)) are measured to assess the clinical significance of results. | 6 months; 9 months; 12 months | |
Other | EuroQual5 (EQ-5D) | Is used to assess general function. The visual analogue scale (VAS) of the EQ-5D will be used as a quantitative measure of health as judged by the woman and her partner ranging between 0-100. | 6 months; 9 months; 12 months | |
Primary | Mean level of pain during penile/vaginal intercourse (PI) | Pain intensity is measured on a scale between 0-10 | 6 months; 9 months; 12 months | |
Secondary | Penetration behavior questionnaire (PBQ) | The PBQ has seven questions inquiring about the woman's experience during the last month with the following aspects of vaginal penetration: full vaginal penetration with the penis of the partner, self-insertion in the vagina of one finger by the woman, self-insertion in the vagina of two fingers by the woman, insertion in the vagina of one finger by the partner, insertion in the vagina of two fingers by the partner, and self-insertion in the vagina of another object (such as a tampon or a dildo) by the woman and by the partner. Answering categories are as follows: (a) not attempted; (b) attempted, but unsuccessful; (c) attempted and sometimes successful; and (d) attempted and always successful. The total of the scale is calculated and ranges between 4-28. | 6 months; 9 months; 12 months | |
Secondary | Genital pain rating questionnaire (GPQ) | Genital pain experienced by touch and penetration of the vagina will be assessed with the 7- item Genital Pain rating Questionnaire (GPQ). Response categories vary from 0 (not at all) to 10 (worst pain imaginable). The questionnaire consist of two sub-scales: the first sub-scale 'pain on touch and finger insertion'' consists of 6 items (pain by touch of the vulva by the patient herself, pain by touch of the vulva by the patient's partner, pain during insertion of one/two own finger(s) into the vagina, and pain during insertion of one/two finger(s) of the patient's partner) into the vagina. The range of the sub-scale is 0-60. The second sub-scale is 1 item related to pain during intercourse (0-10). | 6 months; 9 months; 12 months | |
Secondary | Female Sexual Function Index (FSFI) | Female Sexual functioning will be assessed with the 19-item Female Sexual Function Index (FSFI). It covers six domains of sexual functioning: sexual desire, sexual arousal, lubrication, orgasm, sexual satisfaction, and sexual pain. The answers are given on a Likert scale ranging from 0 or 1 to 5, depending on item. For the current study, the total FSFI score will be used, excluding the three items on sexual pain, which gives an indication of the sexual functioning during the past four weeks. The total score ranges between 2-30 with higher scores indicating higher sexual function. | 6 months; 9 months; 12 months | |
Secondary | Female Sexual Distress scale (FSDS) | Sexual related personal distress will be assessed with the 12-item Female Sexual Distress scale (FSDS). Questions are answered on a 0-4 Likert scale and the total score ranges from 0-48 with higher scores indicating higher sexual distress. | 6 months; 9 months; 12 months | |
Secondary | Global Measure of Sexual Satisfaction Scale (GMSEX) | Sexual satisfaction will be assessed with the 5-item Global Measure of Sexual Satisfaction Scale (GMSEX). GMSEX consist of five 7-point dimensions of sexual satisfaction ranging from "Good" to "Bad", "Pleasant" to "Unpleasant", "Positive" to "Negative", "Satisfying" to "Unsatisfying", and "Valuable" to "Worthless". Total scores range from 5-35, with higher scores indicating greater sexual satisfaction. | 6 months; 9 months; 12 months | |
Secondary | Vaginal Penetration Cognition Questionnaire (VPCQ) | Positive and negative cognitions and beliefs regarding vaginal penetration will be assessed with the 22-item Vaginal Penetration Cognition Questionnaire (VPCQ). The VPCQ is a 22-item self-report measure using positive and negative statements about vaginal penetration and is answered on a 7-point Likert scale. Possible answers range from "0 = not at all applicable" to "6 = very strongly applicable." The VPCQ consists of 5 subscales: Control Beliefs (4 items), Catastrophic and Pain Beliefs (5 items), Self-Image Beliefs (6 items), Positive Beliefs (5 items), and Genital Incompatibility Beliefs (2 items). | 6 months; 9 months; 12 months | |
Secondary | Painful Intercourse Self-Efficacy Scale (PISES) | Pain self-efficacy beliefs will be assessed using the 20-item Painful Intercourse Self-Efficacy Scale (PISES), it consists of three sub-scales: self-efficacy for controlling pain during intercourse, for sexual function, and for other symptoms. Answers are given on a 10-point scale ranging from (10) very uncertain to (100) very certain. | 6 months; 9 months; 12 months | |
Secondary | CHAMP Sexual Pain Coping Scale (CSPCS) | Avoidance and endurance coping behaviors during penetration will be assessed with the 12-item CHAMP Sexual Pain Coping Scale (CSPCS). This measure consists of three sub-scales: avoidance, endurance and alternative strategies. Respondents rate their agreement of each statement between 1 ("Never true") and 7 ("Always true"). Total scores range from 4-28 on each sub-scale. | 6 months; 9 months; 12 months | |
Secondary | Maudsley Marital Questionnaire (MMQ) | Relationship satisfaction will be assessed with the 10 items of the marital dissatisfaction subscale of the Maudsley Marital Questionnaire MMQ. Possible range 0-80 with higher scores indicating greater dissatisfaction. | 6 months; 9 months; 12 months | |
Secondary | Approach and Avoidance Sexual Goals (AASG) | To assess sexual motives and goals the 15-item Approach and Avoidance Sexual Goals (AASG) measure will be used. Participants can rate the importance of 9 approach and 6 interpersonal goals in influencing their decision to engage in sex on a 7 point scale. | 6 months; 9 months; 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03935698 -
Physiotherapy Treatment in Women With Dyspareunia Following Gynecological Cancer: a Pilot Study
|
N/A | |
Completed |
NCT02253173 -
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT03184077 -
Rapidly Absorbing Polyglactin 910 Versus Poliglecaprone 25 for Laceration Repair
|
N/A | |
Recruiting |
NCT05445115 -
The Mollie Study, a Study to Evaluate the Safety and Efficacy of the Mollie Medical Device
|
N/A | |
Withdrawn |
NCT03666819 -
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
|
Phase 2 | |
Active, not recruiting |
NCT03681678 -
Laser Therapy for Treatment of Urogenital Symptoms in Women
|
||
Completed |
NCT04955418 -
Effects of Epi-no Device on Pelvic Floor Dysfunctions
|
N/A | |
Completed |
NCT05834088 -
Effects of Myofascial Release With and Without Thiele Massage
|
N/A | |
Terminated |
NCT03185169 -
GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors
|
Early Phase 1 | |
Completed |
NCT03307044 -
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
|
N/A | |
Completed |
NCT05617820 -
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
|
Phase 3 | |
Recruiting |
NCT03714581 -
Laser Therapy Following Radiotherapy for Gynecological Cancer
|
N/A | |
Completed |
NCT04659668 -
Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.
|
N/A | |
Completed |
NCT03199534 -
A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction
|
Phase 4 | |
Completed |
NCT00318500 -
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
|
Phase 2 | |
Recruiting |
NCT05540353 -
Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients With Endometriosis.
|
N/A | |
Completed |
NCT03178825 -
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
|
N/A | |
Completed |
NCT04389489 -
Postpartum Sexual Function in Pregnant Women With COVID-19
|
||
Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A | |
Completed |
NCT01935063 -
Study to Compare the Efficacy of Cognitive-behavioral Couple Therapy and Lidocaine for Provoked Vestibulodynia
|
N/A |